1. Show article details.

    Investors in health-care stocks get rich as M&A booms

    MarketWatch – 9:42 AM ET 03/18/2015

    Deal premiums rise as takeover battles become common. Valeant Pharmaceuticals' (VRX) winning takeout bid for Salix Pharmaceuticals (SLXP) sheds light on other potential windfalls for investors as health-care companies feel the urge to merge. Valeant raised its cash offer for Salix to $173 from $158 a share, trumping a rival cash-and-stock bid of $172.50 a share from Endo International.

  2. Show article details.

    Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments

    GlobeNewswire – 4:00 PM ET 03/12/2015

    - SUNRISE Phase III Lung Cancer Trial On Track to Complete Enrollment by Calendar Year-End - - Encouraging and Consistent Data from Immuno-Oncology Development Program Continue to Support Bavituximab's Immunostimulatory Mechanism - - Avid Bioservices Increases Revenue Guidance to Between $23 and $25 Million for Full Fiscal Year 2015 Based on Strong Demand for Services – TUSTIN, Calif., March...

  3. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

    GlobeNewswire – 4:00 PM ET 03/10/2015

    Peregrine Pharmaceuticals, Inc. (PPHM) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2015 to holders of record at the close of business on March 20, 2015.

  4. Show article details.

    Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015

    GlobeNewswire – 4:00 PM ET 03/05/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced that it will report financial results for the third quarter fiscal year 2015 ended January 31, 2015 on March 12, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time.

  5. Show article details.

    Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference

    GlobeNewswire – 4:00 PM ET 03/02/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, announced that Steven W. King, president and chief executive officer, will present a...

  6. Show article details.

    Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma

    Market Wire – 8:30 AM ET 02/09/2015

    02/09/15 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone.

  7. Show article details.

    Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma

    PR Newswire – 8:40 AM ET 01/28/2015

    LONDON, January 28, 2015 Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (HALO), Agenus Inc. (AGEN), Biogen Idec Inc. (BIIB), ACADIA Pharmaceuticals Inc. (ACAD), and Peregrine Pharmaceuticals Inc. (PPHM). Free research report on Halozyme Therapeutics (HALO) can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%20Therapeutics&d=28-Jan-2015&s=HALO.

  8. Show article details.

    Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium

    Market Wire – 9:30 AM ET 01/16/2015

    01/16/15 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

  9. Show article details.

    Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer

    Market Wire – 8:00 AM ET 12/12/2014

    12/12/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine signaling pathway, today announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9...

  10. Show article details.

    Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments

    Market Wire – 4:00 PM ET 12/10/2014

    12/10/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, today announced financial results for the second quarter of fiscal year 20...

  11. Show article details.

    Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity

    Market Wire – 8:05 AM ET 12/10/2014

    12/10/14 -- Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (PPHM), today announced it has initiated an expansion of its biomanufacturing capacity.

  12. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

    Market Wire – 4:00 PM ET 12/09/2014

    12/09/14 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on January 2, 2015 to holders of record at the close of business on December 19, 2014.

  13. Show article details.

    Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014

    Market Wire – 4:00 PM ET 12/03/2014

    12/03/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year 2015 ended October 31, 2014 on December 10, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Standard Time.

  14. Show article details.

    Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer

    Market Wire – 7:30 AM ET 11/10/2014

    11/10/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the presentation of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the Society for Immunotherapy of Cancer's 29th Annual Meeting and Associated Programs.

  15. Show article details.

    Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma

    Market Wire – 7:45 AM ET 11/07/2014

    11/07/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the first of four presentations of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab.

  16. Show article details.

    Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer

    Market Wire – 9:41 AM ET 10/30/2014

    10/30/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the presentation of data from the Phase Ib investigator-sponsored trial of its immunotherapy bavituximab in combination with the chemotherapies pemetrexed and carboplatin in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer.

  17. Show article details.

    Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection

    Market Wire – 8:00 AM ET 10/15/2014

    10/15/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the publication of a peer-reviewed manuscript related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus-infected cells in vitro.

  18. Show article details.

    Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment

    Market Wire – 8:00 AM ET 10/06/2014

    10/06/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the presentation of preclinical data related to the company's immuno-oncology development program and its lead drug candidate bavituximab, a phosphatidylserine-targeting antibody.

Page:

Today's and Upcoming Events

  • Jul
    14

    PPHM to announce Q4 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Mar
    12

    PPHM Earnings Conference Call at 4:30 PM Listen

  • Mar
    12

    PPHM to announce Q3 earnings

    • Next earnings date: 7/14/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.